Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâ€™s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	10.98M 9.81M 9.15M 8.31M 15.66M 1.06B 15.78M 110M 42.97M 540M 41.22M 40.33M 1.74B	P/E 2024	-3.13x	P/E 2025	0.13x
Enterprise Value	24.8M 22.16M 20.68M 18.78M 35.37M 2.4B 35.64M 248M 97.07M 1.22B 93.12M 91.1M 3.92B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	56.48%	Yield 2024 *	-	Yield 2025	-

14/08	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
23/07	Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding	CI
10/07	Oncotelic Therapeutics, Inc. announced that it expects to receive $0.71184 million in funding	CI
08/07	Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites	CI
29/06	Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003	CI
23/06	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
19/06	Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026	CI
18/06	Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services	CI
17/06	TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility	CI
08/06	Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development	CI
15/05	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
14/05	Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus	CI

07/10	Oncotelic Therapeutics, Inc. - PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026	AQ
05/10	PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026	AQ
03/08	Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th	AQ
23/07	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle Technology Supporting the Ongoing Clinical Development of Sapu003	AQ
22/07	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)	AQ

Manager	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	61	22/04/2019
Amit Bhupendra Shah DFI	Director of Finance/CFO	59	01/07/2019
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	77	06/01/2020

Director	Title	Age	Since
Vuong Trieu CHM	Chairman	61	22/04/2019
Steven King BRD	Director/Board Member	61	11/05/2020
Anthony Maida BRD	Director/Board Member	61	11/05/2020

Mateon Therapeutics, Inc. Stock Other OTC

Stocks

MATN

US57667K1097

Biotechnology & Medical Research

Valuation: Mateon Therapeutics, Inc.

Latest news: Mateon Therapeutics, Inc.

Press Releases: Mateon Therapeutics, Inc.

Managers and Directors: Mateon Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATEON THERAPEUTICS, INC.	-.--%	-.--%	-	-	10.98M
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.68B
ARGENX SE	-18.15%	-18.68%	-0.41%	+46.55%	58.7B
LONZA GROUP AG	-1.91%	+1.39%	+4.33%	+32.49%	48.36B
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	43.05B
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	42.48B
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	41.39B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.29B
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	23.93B
INSMED INCORPORATED	-3.32%	-10.86%	-37.32%	+316.28%	22.22B
Average	-2.00%	-2.18%	+42.37%	+152.14%	42.9B
Weighted average by Cap.	-2.45%	-1.56%	+48.78%	+144.26%

	2024	2025
Net sales	-	-
Net income	-4.52M -4.04M -3.77M -3.43M -6.45M -438M -6.5M -45.32M -17.7M -223M -16.98M -16.62M -715M	249M 223M 208M 189M 355M 24.11B 358M 2.5B 976M 12.26B 936M 916M 39.42B
Net Debt	13M 11.62M 10.84M 9.84M 18.54M 1.26B 18.68M 130M 50.88M 640M 48.81M 47.76M 2.06B	13.82M 12.35M 11.52M 10.47M 19.71M 1.34B 19.86M 138M 54.1M 680M 51.9M 50.77M 2.19B